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ABSTRACT
The role of intestinal human pregnane X receptor (PXR) in colon
cancer was determined through investigation of the chemo-
preventive role of rifaximin, a specific agonist of intestinal human
PXR, toward azoxymethane (AOM)/dextran sulfate sodium
(DSS)–induced colon cancer. Rifaximin treatment significantly
decreased the number of colon tumors induced by AOM/DSS
treatment in PXR-humanized mice, but not wild-type or Pxr-null
mice. Additionally, rifaximin treatment markedly increased the
survival rate of PXR-humanizedmice, but not wild-type or Pxr-null
mice. These data indicated a human PXR–dependent therapeutic
chemoprevention of rifaximin toward AOM/DSS-induced colon
cancer. Nuclear factor k-light-chain-enhancer of activated
B cells–mediated inflammatory signaling was upregulated
in AOM/DSS-treated mice, and inhibited by rifaximin in PXR-
humanized mice. Cell proliferation and apoptosis were also
modulated by rifaximin treatment in the AOM/DSS model.
In vitro cell-based assays further revealed that rifaximin regulated
cell apoptosis and cell cycle in a human PXR-dependent manner.
These results suggested that specific activation of intestinal human
PXR exhibited a chemopreventive role toward AOM/DSS-induced
colon cancer by mediating anti-inflammation, antiproliferation, and
proapoptotic events.
Introduction
Colorectal cancer is one of the most common forms of fatal
cancer in the world; however, the underlying molecular patho-
genesis and effective strategies for prevention and treatment of
spontaneous colorectal cancer are not fully understood (le Clercq
and Sanduleanu, 2014). Chronic inflammation is a known risk
factor for carcinogenesis, and accumulated data indicate that up
to 15% of human cancer incidence is associatedwith inflammation
(Drexler and Yazdi, 2013). Inflammatory bowel diseases, such as
ulcerative colitis and Crohn’s disease, dramatically increase the
risk of colorectal cancer. Proinflammatory pathways and media-
tors including eicosanoids catalyzed by cyclooxygenases (COXs) or
5-lipoxygenase and cytokines/chemokines promote tumorigenesis.
Anti-inflammatory strategies, such as inhibition of COXs by
nonsteroidal anti-inflammatory drugs, are among the most
promising approaches for the chemoprevention of colon cancer
(Stolfi et al., 2013). In addition, the importance of inflammation
is further highlighted by the dependence of tumor type and
progression on activation of nuclear factor k-light-chain-enhancer
of activated B cells (NF-kB) (Mladenova et al., 2013). The NF-kB
pathway activation observed during inflammatory bowel diseases
may contribute to tumor formation by providing antiapoptotic
survival signals to the colonic epithelial cells (Onizawa et al.,
2009). Indeed, inmice harboring amutation in intestinal inhibitor
of kB kinase b that leads to suppression of the NF-kB pathway,
colon tumorigenesis was significantly attenuated (Greten et al.,
2004).
Rifaximin (Xifaxan; Salix Pharmaceuticals, Raleigh, NC), a
nonsynthetic antibiotic that has low gastrointestinal absorption
while retaining antibacterial activity within the intestine, was
approved in 2004 for therapy of traveler’s diarrhea and in 2010
for therapy of hepatic encephalopathy due to its antibiotic-based
inhibition of ammonia-producing enteric bacteria that reduces
circulating gut-derived ammonia in patients with cirrhosis
(Mullen et al., 2014). In addition, numerous clinical trials
revealed that rifaximin has efficacy toward irritable bowel
syndrome, presumably as a result of alteration of intestinal
microbiota (Xu et al., 2014). Thus, rifaximin has therapeutic
applications beyond its antibiotic activity, and is especially
attractive due to its minimal systemic absorption and safety
profile. A previous study indicated that rifaximin is the gut-
specific agonist of human pregnane X receptor (PXR, NR1I2)
(Ma et al., 2007) and is also a potential drug candidate for
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acute colitis through its anti-inflammatory activity, due in part
to inhibition of the NF-kB signaling cascade through specific
activation of intestinal PXR (Cheng et al., 2010). Therefore, the
chemopreventive role of rifaximin toward colitis-associated colon
cancer was examined in the present study.
The experimental colitis-mediated mouse colon cancer model
was created through the injection of azoxymethane (AOM),
a mutagenic agent, and dextran sulfate sodium (DSS), a
proinflammatory chemical (Kohno et al., 2005). This model was
used in the present study to determine the role of specific
activation of intestinal human PXR in the suppression of
AOM/DSS-induced colon cancer. The therapeutic role of rifaximin
toward AOM/DSS-induced colon cancer in PXR-humanized, wild-
type, and Pxr-null mice was evaluated. Furthermore, the effect
of rifaximin on proinflammatory cytokines and apoptosis during
development of colitis and colon carcinogenesis was also
investigated. The results suggested that specific activation of
intestinal PXR by rifaximin might exert a chemopreventive
role in AOM/DSS-induced colon cancer through inhibition of
the NF-kB pathway and induction of cellular apoptosis.
Materials and Methods
Animals and Chemicals. Male PXR-humanized, wild-type, and
Pxr-null mice were housed in temperature- and light-controlled rooms
and were given water and pelleted chow ad libitum. All animal
experiments were carried out in accordance with the Institute of
Laboratory Animal Resources guidelines and approved by the National
Cancer Institute Animal Care and Use Committee. Rifaximin (Xifaxan)
was provided by Salix Pharmaceuticals, Inc. (Morrisville, NC.). AOM
was purchased fromSigma-Aldrich (St. Louis,MO) and DSS (molecular
mass 36,000–50,000 Da) was from MP Biochemicals (Solon, OH).
AOM/DSS-Induced Colon Cancer Model and Rifaximin
Treatment. Before starting the experiments, mice were acclimatized
for 1 week. Two- to three-month-old PXR-humanized, wild-type, and
Pxr-null male mice were divided into a control group, AOM/DSS group,
and AOM/DSS1rifaximin group (n 5 20 for each group). To induce
colon cancer, PXR-humanized, wild-type, and Pxr-null mice were given
an intraperitoneal injection with 10mg/kg AOM in 0.1 ml of phosphate-
buffered saline (PBS) followed by three cycles of 2% DSS in drinking
water for 1 week and normal drinking water for 2 weeks. The AOM/
DSS1rifaximin group was administered rifaximin in the 10 mg/kg
rifaximin–containing AIN-93Gdiet (Dyets Inc., Bethlehem, PA), whereas
mice in the AOM/DSS group and control group received the AIN-93G
diet without rifaximin. This dose of rifaximin is equivalent to oral
administration of 1 mg/kg per day for each mouse. All mice in the
AOM/DSS1rifaximin group received rifaximin-containing diet for
1 week before the AOM/DSS treatment until the end of the ex-
periment. Bodyweights and food andwater consumptionweremonitored
once per week throughout the experiment. Clinical assessment of all
DSS/AOM-treated animals for body weight, stool consistency, rectal
bleeding, and general appearance was performed weekly. At day 180 of
the experiment, all mice were killed, and whole colorectal tissues were
collected for biochemical and pathologic analyses.
Macroscopic and Histopathologic Evaluation Analysis. Af-
ter killing the mice, the colons were excised from the ileocecal junction
to the anal verge and flushed with PBS. Blood was collected for the
preparation of serum. Colons were weighed and colon length (from the
colocecal junction to the rectum) was measured for assessment of
morphologic changes. The colon was opened longitudinally. Gross exam-
ination was performed to measure the pattern of tumor development,
including quantity, size, and the location of each tumor within the large
bowel. The tumor incidence was defined as the number of mice with
tumors/total mice in the group. For histologic analysis, the colon tissues
were fixed in 10% formalin for 24 hours, followed by paraffin embedding.
The incidence of tumorswith a diameter.4mmwas also assessed because
most large tumors with a diameter.4 mm that were examined contained
carcinoma components.
Short-Term Antiproliferation Effect of Rifaximin. To observe
the short-term antiproliferation role of rifaximin,PXR-humanized (n5 9),
wild-type (n5 9), and Pxr-null (n5 9) mice were given an intraperitoneal
injection with 10 mg/kg AOM dissolved in 0.1 ml of PBS followed by one
cycle of 2%DSS in drinkingwater for 1week. Among them, fourmicewere
used for bromodeoxyuridine (BrdU) staining experiments. Mice were
injected with 200 mmol/kg body weight of BrdU. After 1 hour, the mice
were killed and the colons taken for BrdU staining as detailed in a
previous study (Wang et al., 2008). The BrdU labeling index was
calculated using the ratio of BrdU staining–positive cell number
versus the total cell number. The colons taken from the other five mice
were subjected to quantitative polymerase chain reaction (qPCR)
analysis for specific mRNAs.
qPCR Analysis. Total RNA was extracted from colon tissues
of each mouse using TRIzol reagent (Invitrogen, Carlsbad, CA), and
qPCR was performed using cDNA generated from 1 mg of total RNA
with SuperScript II Reverse Transcriptase (Invitrogen). Primers for
qPCR were designed using the Primer Express software (Applied
Biosystems, Foster City, CA); sequences are available upon request.
qPCR reactions were carried out using SYBR Green PCR master mix
(SuperArray, Frederick, MD) using an ABI Prism 7900HT Sequence
Detection System (Applied Biosystems). Values were quantitated using
the comparative cycle threshold method, and results were normalized
to mouse b-actin.
Cell Apoptosis Assays by Flow Cytometry. Human colonic
epithelial cells, HT-29, were grown at 37°C with 5% CO2 in Dulbecco’s
modified Eagle’s medium (Invitrogen, Grand Island, NY) supplemented
with 10% fetal bovine serum (Gemini Bio-Products, Woodland, CA) and
1% penicillin-streptomycin (Invitrogen). HT-29 cells were seeded at a
density of 5 104 cells/well in 24-well plates. Expression vectors for human
PXR and retinoid X receptor a (RXRa) constructs were transfected
into cells using Fugene transfection reagent (Roche, Indianapolis,
IN). Twenty-four hours post-transfection, the cells were incubated
with dimethylsulfoxide (vehicle) or rifaximin for an additional
24 hours, followed by cell apoptosis analysis as follows. Cells were
treated with fluorescein isothiocyanate–conjugated annexin V in
conjunction with propidium iodide (PI), which stains necrotic cells to
identify apoptotic cells measured by flow cytometry (BD Biosciences,
San Jose, CA). Cells were differentiated in early apoptosis (annexin V1,
PI2) from those in late apoptosis (annexin V1, PI1) stage. To confirm
expression of the human PXR in the transfected HT-29 cells, nuclear
extracts of cells 24 hours after transfection were prepared using the
NE-PER kit (Pierce/Thermo Scientific, Rockford, IL). Nuclear extracts
(20 mg) were loaded on a SDS–polyacrylamide gel, and western blotting
was carried outusingaHumanPXRCommon/NR112monoclonal antibody
(mAb) (Clone H4417; R&D Systems, Minneapolis, MN) and Histone
H3 (D2B12) XR rabbit mAb (Cell Signaling Technology, Danvers, MA)
diluted 1:1000 in 5% skim milk. Nuclear extracts of liver tissues
from PXR-humanized and Pxr-null mice were also loaded as a positive
and negative control, respectively. The human PXR mAb recognizes
human PXR1 and 2. The immunogen was amino acids 1–40 of human
PXR. Primers used for qPCR are shown in the Supplemental Fig. 5
legend.
Statistics. Experimental values are expressed as the mean6 S.D.
Statistical analysis was performed with two-tailed Student’s t tests,
and P values ,0.05 were considered to be statistically significant.
Results
Rifaximin Prevents AOM/DSS-Induced Colon Carci-
nogenesis in a Human PXR–Dependent Manner. PXR-
humanized mice with AOM/DSS1rifaximin treatment had
the highest survival rate among PXR-humanized, wild-type,
and Pxr-null mice treated with AOM/DSS1rifaximin (Fig. 1A).
However, there were no significant differences in survival rates
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among the three mouse lines treated with AOM/DSS only
(Supplemental Fig. 1). The AOM/DSS-induced colon cancer pro-
duced similar total tumor numbers per colon in PXR-humanized,
wild-type, and Pxr-null mice fed a control diet (Fig. 1B).
However, rifaximin treatment led to reduced tumor numbers
only in PXR-humanized mice in comparison with wild-type
and Pxr-null mice (Fig. 1C). Total tumor incidence in the
PXR-humanized mice treated with AOM/DSS1rifaximin was
42% compared with 100% in the AOM/DSS group, and 100% in
the wild-type and Pxr-null mice treated with AOM/DSS and
AOM/DSS1rifaximin (Fig. 2A). Among the tumors found
in the AOM/DSS group in the PXR-humanized mice, 24%
had diameters .4 mm (Fig. 2B) with histologic characteristics
of adenocarcinomas (Supplemental Fig. 2). All of the tumors in
the PXR-humanized mice treated with AOM/DSS1rifaximin
Fig. 1. Treatment with rifaximin prevents AOM/DSS-induced colon carcino-
genesis inPXR-humanizedmice. (A) Survival rate ofPXR-humanized (hPXR),
wild-type (WT), and Pxr-null mice with rifaximin treatment in the AOM/DSS-
induced colon carcinogenesis model (n = 11 per group). **P , 0.01. N.S., not
significant. (B) Tumor numbers in hPXR, WT, and Pxr-null mice without
rifaximin treatment in AOM/DSS-induced colon carcinogenesis. (C) Tumor
number in hPXR, WT, and Pxr-null mice with rifaximin treatment in AOM/
DSS-induced colon cancer. **P , 0.01.
Fig. 2. Tumor incidence in cohort 1 of PXR-humanized (hPXR), wild-type
(WT), andPxr-null mice with or without rifaximin treatment in AOM/DSS-
induced colon carcinogenesis (n = 10 per group). (A) Total tumor incidence in
hPXR, WT, and Pxr-null mice with or without rifaximin treatment in AOM/
DSS-induced colon cancer. (B) Percentage of tumors with diameter .4 mm
in hPXR, WT, and Pxr-null mice with or without rifaximin treatment. (C)
Percentage of tumors with diameter,4 mm in hPXR, WT, and Pxr-null mice
with or without rifaximin treatment.
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were smaller, with diameters ,4 mm (Fig. 2C). Wild-type and
Pxr-null mice treated with AOM/DSS had 10 and 25% .4-mm
diameter tumors, respectively, and when treated with AOM/
DSS1rifaximin, had 4 and 18% with.4-mm diameter tumors,
respectively (Fig. 2B). In a second cohort of PXR-humanized
mice treated with AOM/DSS1rifaximin, there was a 15% tumor
incidence compared with 100% in the AOM/DSS-treated PXR-
humanized group, and 100% for the wild-type and Pxr-null mice
treatedwith AOM/DSSwith orwithout rifaximin (Supplemental
Fig. 3A). In the PXR-humanized mice treated with AOM/DSS,
38% of the tumors were ,4 mm in diameter (Supplemental
Fig. 3B) whereas all of the tumors in the PXR-humanized
mice treated with AOM/DSS1rifaximin were,4mm in diameter
(Supplemental Fig. 3C). Interestingly, in this cohort, thewild-type
mice treatedwithAOM/DSS1rifaximin hadmostly (75%).4-mm
diameter tumors with AOM/DSS1rifaximin treatment (Supple-
mental Fig. 3B). The reason for this difference between the first
cohort of mice (Fig. 2) is not known. Tumor incidence and per-
centage of small and large tumors were similar in both cohorts
of the Pxr-null mice treated with AOM/DSS with and without
rifaximin (Fig. 2; Supplemental Fig. 3). Both cohorts revealed that
rifaximin inhibited AOM/DSS-induced tumorigenesis—notably,
the production of large, .4-mm diameter tumors.
Rifaximin Inhibits the NF-kB Pathway via Human
PXR Activation in Colitis-Associated Colorectal Carci-
nogenesis. To investigate the effects of rifaximin-enriched
diet on the expression of mRNAs encoding proinflammatory
cytokines, qPCRwas used to quantifymRNAs in tumor-adjacent
tissue of the colon. Expression of tumor necrosis factor a (Tnfa)
and interleukin 1b (Il-1b) mRNAs significantly increased after
AOM/DSS treatment (P, 0.01); rifaximin treatment suppressed
the increased expression induced by AOM/DSS inPXR-humanized
mice (Fig. 3). No suppression of rifaximin toward the AOM/DSS-
induced elevated expression of Tnfa and Il-1b mRNAs was found
in wild-type or Pxr-null mice. In PXR-humanized mice, compared
with the AOM/DSS group, expression of inducible nitric oxide
synthase, Il-6, and Il-10 mRNAs was significantly reduced (P ,
0.05) in the DSS/AOM1rifaximin group. However, this effect was
Fig. 3. Expression of humanPXR andNF-kB target genes
in tumor-adjacent tissue of colon inPXR-humanized (hPXR),
wild-type (WT), and Pxr-null mice with or without rifaximin
(RIFax) treatment in AOM/DSS-induced colon carcinogene-
sis [n = 5 for AOM/DSS and AOM/DSS+RIFax groups, n = 4
for the normal control (Con) group]. #P , 0.05, ##P , 0.01
comparedwith control (normal tissue); *P, 0.05, **P, 0.01
compared with AOM/DSS-treated group.
562 Cheng et al.
not observed for wild-type or Pxr-null mice (Fig. 3). These results
indicated that the NF-kB signaling pathway was induced in the
AOM/DSS-induced colon cancer model in PXR-humanized,
wild-type, and Pxr-null mice, and that the NF-kB pathway was
suppressed only in PXR-humanized mice upon rifaximin treat-
ment. Therefore, inhibition of theNF-kBsignaling pathwaymight
contribute to the prevention of AOM/DSS-induced colon cancer in
PXR-humanized mice via human PXR activation by rifaximin.
Effect of Rifaximin on Cell Proliferation and Apo-
ptosis. To explore the effect of rifaximin treatment on pro-
liferation and apoptosis in the inflammation-related colon
cancer mouse model, the expression of several target genes
was investigated. The results revealed that p21 mRNA was
significantly increased in the AOM/DSS1rifaximin group in
comparison with the AOM/DSS group in PXR-humanized
mice, but not in wild-type or Pxr-null mice (Fig. 4). The expression
of mRNAs encoded by genes involved in apoptosis, Bcl-2 and Bclx,
was significantly decreased and significantly increased, respec-
tively, in the AOM/DSS1rifaximin group when compared with
the AOM/DSS group in PXR-humanized mice, but not in wild-
type or Pxr-null mice (Fig. 4). The expression of mRNA encoding
C-myc, an oncoprotein expressed in proliferating and transformed
cells, was also examined (Qu et al., 2014). Suppression of C-myc
mRNA was only observed in AOM/DSS-treated PXR-humanized
mice, and not in wild-type or Pxr-null mice upon rifaximin
treatment, indicating that rifaximin efficiently decreased cell
proliferation via human PXR (Fig. 4). Cyclin-dependent kinases
are a family of protein kinaseswith important roles in regulating
the cell cycle through binding to regulatory proteins called cyclins
(Lim and Kaldis, 2013). Treatment with rifaximin prevented the
increased expression ofCdk andCyclinmRNAs induced by AOM/
DSS in PXR-humanized mice, but not in wild-type or Pxr-null
mice, including Cdk2, Cdk4, Cdk6, Ccnd1, Ccnd2, Ccna2, Ccne1,
and Ccne2 (Fig. 5). To confirm the inhibitory action of rifaximin
toward cell proliferation in PXR-humanized mice, BrdU staining
was performed. Treatment of PXR-humanized mice with rifax-
imin significantly decreased incorporation of BrdU into colon
epithelial cells induced by AOM/DSS treatment when compared
with rifaximin-treatedwild-type andPxr-nullmice (Fig. 6, A andB).
Short-term treatment with rifaximin can activate human intestinal
PXR, but notmouse intestinal PXR (Ma et al., 2007) (Supplemental
Fig. 4), and the expression of the corresponding Cdk and Cyclin
mRNAswas also significantly decreased inPXR-humanizedmice in
comparison with wild-type and Pxr-null mice (Fig. 7).
In Vitro Transfection of Human PXR and Rifaximin
Treatment Increased Apoptosis and Decreased Pro-
liferation in HT-29 Cells. To analyze whether rifaximin can
modulate apoptosis and proliferation in a human PXR–dependent
manner, induction of apoptosis was evaluated in cells transfected
with or without human PXR. Expression of human PXR and
RXRa from the expression vector was demonstrated by analysis
of human PXR mRNA and protein using qPCR and western
blotting, and RXRa mRNA by qPCR (Supplemental Fig. 5). Cells
with either RXRa or PXR/RXRa were simultaneously stained
with PI and annexin V, and monitored by flow cytometry. Cells
were treated with dimethylsulfoxide (control), low-dose rifaximin
(1 mM) and high-dose rifaximin (100 mM). Cells transfected with
the RXRa expression plasmid remained viable throughout the
experiment, indicating that the treatment did not induce apoptosis
without human PXR expression (Supplemental Fig. 6). A low
Fig. 4. Expression of p21, Bcl-2, Bclx, and c-MycmRNAs
in tumor-adjacent tissue of colon inPXR-humanized (hPXR),
wild-type (WT), and Pxr-null mice with or without rifaximin
(RIFax) treatment in AOM/DSS-induced colon carcinogene-
sis [n=5 forAOM/DSSandAOM/DSS-rifaximin group,n=4
for normal control (Con) group]. #P , 0.05 compared with
control (normal tissue); *P, 0.05 comparedwith AOM/DSS-
treated group.
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dose of rifaximin produced negligible influence on apoptosis
and proliferation of HT-29 cells transfected with the human
PXR expression vector. However, a high dose of rifaximin
significantly increased the numbers of total, early, and late
apoptosis, with a slight, although not significant, elevation of
cell numbers in the G0/G1 phase (Fig. 8).
Discussion
Inflammatory bowel disease leads to increased risk of de-
veloping colon cancer. The risk of colon cancer development is
much higher in patients with inflammatory bowel disease than in
the general population (Derikx et al., 2014). The tumor-promoting
effect of inflammation is widely recognized to be related to the
induction of gene mutations or epigenetic alterations, increased
expression of factors involved in carcinogenesis (such as NF-kB
and COX-2), production of reactive oxygen species, and inhibition
of apoptosis and stimulation of cell proliferation (Savari et al.,
2014). It is also widely accepted that chronic inflammation
promotes carcinogenesis by inducing production of a variety of
cytokines and chemokines that produce a localized inflammatory
response by activating NF-kB, which is followed by increased
Fig. 5. Expressions ofmRNAs encoded by cyclin-dependent kinases and cyclin genes in tumor-adjacent tissue of colon inPXR-humanized (hPXR), wild-type (WT),
and Pxr-null mice with or without rifaximin (RIFax) treatment in AOM/DSS-induced colon carcinogenesis mice [n = 5 for AOM/DSS and AOM/DSS+RIFax group,
n = 4 for normal control (Con) group]. #P , 0.05, compared with control (normal tissue); *P , 0.05, **P , 0.01 compared with AOM/DSS-treated group.
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expression of inducible nitric oxide synthase and proinflammatory
cytokines, including tumor necrosis factora and interleukin-6.
These findings have important implications for the development
of colon cancer chemoprevention strategies.
PXR regulates genes involved in the metabolism and disposi-
tion of various xenobiotics and endobiotics (Cheng et al., 2011).
However, several studies reported potentially novel physiologic
functions of PXR, including regulation of inflammatory pathways
(Xie and Tian, 2006). By this mechanism, the role of PXR in the
therapy of acute colitis and colon cancer was investigated. PXR
suppressed the proliferation of colon tumor cells in culture by
modulating the cell cycle at the G0/G1 cell phase by an unknown
mechanism (Ouyang et al., 2010). Forced expression of human
PXR in colon cancer cell lines inhibited proliferation and increased
apoptosis, and the tumor size was significantly suppressed in
a xenograft model (Xie et al., 2009; Ouyang et al., 2010). However,
a contradictory role of PXR in colon cancer also exists. Treatment
of a PXR-expressing colon cancer cell line, LS180, with the PXR
agonist rifampicin inhibited apoptosis. Activation of PXR upregu-
lated the antiapoptotic signaling molecules BAG3, BIRC2, and
MCL-1, and downregulated the proapoptotic factors BAK1 and
p53 (Zhou et al., 2008; Habano et al., 2011). Others showed that
activation of PXR induced tumor aggressiveness in mice and
humans in a fibroblast growth factor 19–dependent manner
(Wang et al., 2011). Based on these studies, the role of PXR in colon
cancer remains unclear, thus the need for further investigation.
Rifaximin is a gut-specific agonist of human PXR, and thus
can be used to investigate the role of intestinal PXR in colon
cancer. However, this can only be accomplished using PXR-
humanized mice since rifaximin does not activate the mouse
PXR. With this agonist, the role of human intestinal PXR in
acute colitis therapy was uncovered (Cheng et al., 2010). The
preventive and therapeutic role of rifaximin in experimental
models of colitis was demonstrated in the PXR-humanized
mouse model, where rifaximin not only prevented colitis before
an inflammatory insult, as revealed by use of the DSS and
2,4,6-trinitrobenzene sulfonic acid–induced murine acute co-
litis models, but also decreased the symptoms after the onset of
colitis (Cheng et al., 2010). These data indicated that treatment
with rifaximin might have value in the long-term prevention
of colon inflammation, and that activation of intestinal PXR
might also be used to prevent inflammation-driven colon cancer.
The present study focused on the efficient therapy of rifaximin
toward ulcerative colitis–associated colorectal cancer using the
AOM/DSS-induced colon cancer model. The results revealed
decreased tumor numbers and total tumor incidence upon
rifaximin treatment only in PXR-humanized mice, but not
in wild-type or Pxr-null mice. The percentage of tumors with
a diameter .4 mm was reduced only in PXR-humanized mice,
and not in wild-type or Pxr-null mice. In addition, survival rates
were markedly increased in PXR-humanized mice compared
with wild-type and Pxr-null mice when rifaximin was adminis-
tered concomitant with AOM/DSS. These results suggest that
rifaximin prevents AOM/DSS-induced colon carcinogenesis in
a human PXR–dependent manner. Furthermore, this study
showed that the expression of cytokines significantly increased
in response to DSS/AOM treatment; these are involved in the
“inflammation–carcinoma sequence” (Okayasu, 2012). Treat-
ment with rifaximin decreased cytokine expression, which was
in line with data showing that oral feeding with rifaximin
modulates and attenuates the colonic inflammation in exper-
imental animal colitis (Cheng et al., 2010). These results
suggested that rifaximin exerts anti-inflammatory and growth
inhibitory effects on colon cancer development by reducing
cytokine expression. These results further demonstrate that
rifaximin has antitumor activity in PXR-humanized mice. This
effect is correlated with decreased proinflammatory cytokines,
attenuated colorectal inflammation, and a lack of NF-kB target
gene expression in the colonic tissue at the end of the ex-
perimental model.
Fig. 6. Colon epithelial cells exhibited lower
proliferation inPXR-humanized (hPXR)mice
than wild-type (WT) and Pxr-null mice upon
short-term treatment with rifaximin and
AOM/DSS. (A) Representative BrdU stain-
ing in colon tissues obtained from hPXR,
wild-type, and Pxr-null mice treated with
rifaximin and AOM/DSS. Arrows indicate
BrdU-positive nuclei. (B) BrdU labeling
index comparison in hPXR, WT, Pxr-null
mice treatedwith rifaximin and AOM/DSS.
**P , 0.01; ***P , 0.001.
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The effects of rifaximin on cell proliferation and apoptosis
were also evaluated. Rifaximin treatment induced apoptosis
and reduced proliferation activity in colon tissues of mice
treated with AOM/DSS. The proliferation-inhibiting properties of
rifaximin can also be demonstrated in the short-term AOM/DSS
treatment model. Moreover, rifaximin displayed the ability to
Fig. 7. Gene expression of cyclin-dependent kinases and cyclin genes in colon tissues in PXR-humanized (hPXR), wild-type (WT), and Pxr-null mice with
short-term treatment with AOM/DSS+rifaximin (n = 5 for each groups). *P , 0.05.
Fig. 8. Apoptosis and cell cycle in HT-29 cells transfected
with human PXR with or without rifaximin treatment,
including total apoptosis, early apoptosis, late apoptosis,
and cell cycle. Human PXR and RXRa expression vectors
were transfected to HT29 cells. These transfected cells
were treated with dimethylsulfoxide or two different con-
centrations of rifaximin. Cont, cell treated with DMSO;
H, cell treated with high dosage (100 mM) of rifaximin;
L, cell treated with low dosage (1 mM) of rifaximin. Cells
were treated in two batches (n = 3 per batch); therefore,
cont1, L1, H1, cont2, L2, and H2 were labeled as listed.
*P , 0.05, compared with the control group; **P , 0.01,
compared with the control group; #P , 0.05, compared
with the low dosage group.
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induce apoptosis and control proliferation in the G0/G1 phase
in a sporadic colon carcinoma cell line transfectedwith a human
PXR expression vector. These results revealed the potential
effects of rifaximin toward colon cancer via regulating cell
proliferation and apoptosis.
In summary, the ability of rifaximin to prevent the devel-
opment of colon carcinogenesis was associated with attenuated
colorectal inflammation and lower tumor incidence only in
AOM/DSS-treated PXR-humanized mice, thus indicating a che-
mopreventive role for specific activation of intestinal human
PXR toward colon cancer. The mechanism is due in part to anti-
inflammation, induction of apoptosis, and inhibition of cell
proliferation.
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